Danaher

IThe business

Think of three places where science becomes a product. A drug plant making a biologic medicine, a research lab sequencing or imaging cells, and a hospital lab running blood and infection tests. Danaher sells into all three. Its filters and resins purify the antibody. Its mass spectrometers and microscopes find the target. Its analyzers read the patient’s sample. The company says it is more than 15 operating companies in three segments, with about 60,000 employees in about 50 countries, run from Washington, D.C. ⁸

Danaher sells into drug plants, labs and hospitals, and most of what it sells is consumed and bought again.

Revenue was $26.3B in 2026 on my estimate: $18.8B in nine months and about $7.5B in the fourth quarter E (estimate). ² The three segments are close in size. Biotechnology, which is Cytiva and Pall, was 29% of nine-month sales. Life Sciences, which is SCIEX, Leica, Beckman Coulter life sciences, IDT, Abcam, Aldevron and others, was 29%. Diagnostics, which is Beckman Coulter, Cepheid, Radiometer, Leica Biosystems and, since June, Masimo, was 41% C (calculated). ³⁸

Look at the margins before the sales. Biotechnology made 25.6% in 2025 and 28.4% in the first nine months of 2026. Diagnostics made 26.7% in 2025 and 21.9% so far this year, because Masimo’s inventory write-up and amortization came in. Life Sciences made 7.1% in 2025, down from 16.9% in 2023, after a $432M trade-name write-down and weak core sales. ⁸³ The business with the best story and the business with the best margin are not the same one.

What recurring means

Of the $18.8B sold in nine months, $15.6B was recurring: consumables, services and leases that customers buy again. Equipment was $3.1B. That is 83% recurring C (calculated). ³ Biotechnology was 90% recurring, Diagnostics 89% and Life Sciences 69% C (calculated). A bioreactor is sold once. The bags, filters, media and resins that run in it are bought every batch. A blood analyzer is placed once, and the reagent cartridges for it are bought for years. Remaining performance obligations, contracts of more than a year not yet recognized, were $7.4B. ³

About 41% of sales are in the United States. North America was 41% of nine-month sales, Western Europe 24%, other developed markets 5% and high-growth markets, which includes China, 30% C (calculated). ³⁸

Bioprocessing, the part everyone watches

Biotechnology is the reason most investors own the stock. Its bioprocessing business sold the single-use systems that drug makers built into plants during the pandemic years. Then customers worked through inventory, and sales fell. Biotechnology sales were $7.2B in 2023, $6.8B in 2024 and $7.3B in 2025, and core sales fell 4.5% in 2024 and rose 6.5% in 2025 C (calculated). ⁸ In 2026 core growth in the segment has run at 4.5% in nine months and 5.0% in the third quarter. In the third quarter the company says bioprocessing core sales rose toward the upper end of mid-single digits, led by consumables. ³²

Orders ran ahead of sales. In the second quarter Rainer Blair, who was then CEO, said bioprocessing orders grew in the mid-teens, even as some large customers moved the timing of shipments out of the quarter. ⁵⁴ That is the cleanest hint that revenue could catch up, and it is the company’s statement, not something I can check. A mid-teens order rate that fails to turn into sales would be a different story.

Respiratory tests and the Cepheid swing

Diagnostics carries a swing factor. Cepheid’s rapid molecular tests for flu, COVID and other respiratory infections sold about $1.9B in 2025 and are guided to about $1.5B in 2026, a headwind of low single digits on core growth C (calculated). ² The company now reports core growth with and without these tests. In the first quarter, with a light respiratory season, core growth was only 0.5%, and 3.0% without the tests. ⁶ Without them, core sales rose 5.5% in the third quarter, and with them 3.0%.

What changed in 2026

Three things changed this year, and all three cost money.

• Masimo. Danaher agreed on 16 February to buy the pulse-oximetry and patient-monitoring company for $180.00 a share in cash, and closed on 10 June at about $9.8B net of cash. Masimo had about $1.5B of revenue in 2025. It brought $4.9B of goodwill and $5.0B of intangible assets. ¹⁷³
• StatLab. On 28 September, the first day of the fourth quarter, it bought a provider of pre-analytical consumables and equipment for pathology labs, for about $1.4B including debt. It had about $250M of 2025 revenue. ³
• A new chief executive. Julie Sawyer Montgomery, who ran Beckman Coulter Diagnostics from 2020 to 2022, took over on 1 October. Rainer Blair stays as a senior adviser to the end of the year. ¹⁵

At the end of 2025 net debt was $13.8B. On 25 September gross debt was $26.5B and cash $5.7B, so net debt was $20.8B, and StatLab added $1.4B C (calculated). ³⁸ I come back to that in Valuation.

IIThe moat

The question is why a customer keeps paying Danaher, and what it would take for them to stop.

Start with the way the products are sold. A drug maker designs a manufacturing process around specific filters, resins and bags and files it with regulators. Changing a component means testing again, and the drug being made may be worth billions a year. That is my reading of how the business works, not a statement in the filings. What the filings show is the outcome: recurring revenue of 83% and a segment, Biotechnology, that earned 24.9% in 2024, a year its sales fell 6%. ³⁸

In diagnostics, the instrument sits in the lab and the reagents are bought for years. The 10-Q describes the consumables sold for use with Danaher’s equipment as typically critical to its use. ³ A hospital that has trained staff and validated results does not swap a platform for a small saving.

What the numbers say

Gross margin was 59.1% in 2025, against 55.3% in 2016 as first reported. R&D was $1.6B, 6.5% of sales. ⁸¹³ Operating margin before acquisition amortization and impairments was about 28% in 2025 C (calculated). In the third quarter of 2026 it was 29.0% C (calculated). ²³ Thermo Fisher, the nearest large rival in lab tools, made an adjusted operating margin of 24.5% in the same quarter. ²¹ The two companies define adjusted differently, so I treat the gap as real but loose.

The return line is the one to read slowly. Danaher earns a high margin on its sales, and still earns only about 6.5% to 8.6% on the money that has been put into it, because it paid a lot for what it bought. Goodwill and acquired intangibles were $68.4B at 25 September, or 73% of total assets C (calculated). ³ My required return is 8.0%. A great margin on sales and an ordinary return on capital can sit together, and here they do.

Where the edge is thinner

• Price. The 10-K shows price decreases in Diagnostics of 1.0% in 2025 and 1.5% in nine months of 2026, mostly from volume-based buying and reimbursement changes in China. The company as a whole took a net 0.5% cut in the quarter and in the nine months. ⁸³ A business with a wide moat usually raises price.
• Equipment. Equipment is 17% of sales and it follows customer budgets. Academic and government demand is described as improved but muted. ³
• Life Sciences. Core sales fell 1.5% in 2025 and 2.0% in 2024. Operating profit fell from $1,209M in 2023 to $520M in 2025. The segment has absorbed IDT, Aldevron and Abcam, and the figures do not yet show the payoff. ⁸
• Purchasers with power. Governments and managed-care groups are centralizing purchasing, and China has run a volume-based procurement program that cut prices on diagnostic tests. The 10-K says so in its risk factors. ⁸

IIIThe competitive advantage

The 10-K does not name rivals. It says Danaher competes with a wide mix, including well-resourced newer entrants, makers in low-cost locations and large companies with strong sales and research. ⁸ For a figure comparison I use the one large rival whose latest results are on file, Thermo Fisher.

Danaher wins on adjusted margin and on a recurring base. It loses on growth this quarter: Thermo Fisher’s organic growth was 6%, double Danaher’s core figure, and 5.5% without respiratory tests is still a little behind. ²¹² The new CEO’s own words are telling. She said the aim is for Danaher to become a company that “unambiguously gains share.” ² A leader does not usually need to say that.

Where Danaher wins

• Breadth in bioprocessing. Cytiva and Pall together cover the whole chain from cell culture to filtration and fill. A drug maker can buy more than one step from one supplier. ⁸
• A method. The Danaher Business System is a set of continuous-improvement tools that the 10-K says unites the businesses, with growth, lean, leadership and fundamentals as its four pillars. ⁸ It is the reason the company says it can raise the margin of what it buys. Masimo is the current test: the Diagnostics segment margin fell 5.7 points in the third quarter, 2.95 points of it from the one-time inventory write-up, and 3.65 points from the dilution of acquired businesses. ³
• Cash. Free cash flow from continuing operations was $5.3B in 2025 and $4.0B in nine months of 2026, up 13% C (calculated). ⁷²

Where it loses

• China. Sales to China were $3,143M in 2023, $2,805M in 2024 and $2,631M in 2025, from 13.2% of sales to 10.7% C (calculated). ⁸ In the third quarter of 2026 core growth in China was high single digit, led by Biotechnology and Life Sciences. ³ The decline in diagnostics there came from policy, not from rivals taking share, and the 10-K assumes the company is moving past the peak of those policy headwinds. That is its view. The 10-K also notes China’s tariffs and export controls. ⁸
• Share. Core sales growth in 2025 was 2.0% for the company, 1.5% for Diagnostics and minus 1.5% for Life Sciences. A company with a wide advantage would be expected to grow with its markets, and I cannot tell from filings how fast those markets grew.
• Cycles. Bioprocessing customers bought too much in 2021 and 2022, and sales then fell. The class action that followed claimed misleading statements about bioprocessing revenue between January 2022 and October 2023. It settled, the court approved it in September 2026, and the company says the cost is covered by insurance. ³

IVManagement

A company of this size is the sum of its parts and the people who decide where the money goes. At Danaher that has meant two founders, a method and a long line of purchases. The set of people changed a great deal in the last four months, so I start with who is in charge now.

Who runs it

• Steven Rales, 74, Chairman, and Mitchell Rales, 69, Chairman of the Executive Committee, are the co-founders. Both have been directors since 1983 and both serve as executive officers. ¹⁴¹⁵
• Julie Sawyer Montgomery, 54, became President and CEO on 1 October 2026. She joined in 2017, ran Beckman Coulter Diagnostics from 2020 to 2022 and was an executive vice president from 2024. ¹⁵ She is the first CEO since Rainer Blair, who stays as a senior adviser to 31 December and a consultant to 31 March 2027. ¹⁵
• Matthew Gugino is chief financial officer, a role the 2026 proxy still gave to Matthew McGrew for 2025. ¹⁴¹⁵
• On 9 October the board added two members, Daniel Comas, a former Danaher CFO who consulted for the company until 30 September and was paid $525,000 in 2025, and Robert Hershberg, a former biotech chief executive. Alan Spoon will retire at the 2027 meeting. The board has 13 members. ¹⁶

How they are really paid

Money follows what pays. At Danaher the main measure has been adjusted earnings per share. That figure leaves out the amortization of acquired intangibles, which was $1,697M before tax in 2025, and the cost of the stock awards the board calls special. So a purchase lifts adjusted earnings by the profit it brings, and costs nothing in the measure for the price paid beyond the interest. ¹⁴⁷² That is not wrong or wicked. It is how most companies that report adjusted figures pay. It also means the pay plan has no brake on buying.

In early 2026 the board changed the plan. The annual bonus now rests 70% on company results and 30% on personal goals. The company part is adjusted operating income (43%), core revenue growth (36%) and the ratio of free cash flow to adjusted net income (21%). Long-term awards are 60% performance shares, 20% options and 20% time-vested shares. Half of the performance shares depend on three-year adjusted EPS and half on the shareholder return against the S&P 500 Health Care Index. ¹⁴ Adjusted operating income also leaves out amortization. The cash ratio is the one measure that would bite if purchases did not turn into cash.

At 234.93, the founders’ options are in the money by $40.15 a share, or about $40M each C (calculated). ¹⁵¹ The strike of $194.78 sits 20% above the 15 May low of $161.91 and 20% below the January high of $242.05 C (calculated). ²⁵¹ Four and five years is a long vesting period, and the awards pay for a higher share price. They do not pay for cash per share, which is what an owner is paid in.

How much of their own money is in

A lot, and the founders carry most of it. Steven Rales owns or controls 42.2M shares, 6.0% of the company, and Mitchell Rales 33.0M shares, 4.7%. Together that is 75.2M shares, 10.7%, worth about $17.7B at the close C (calculated). ¹⁴¹ The proxy says 31.0M of Steven’s shares and 3.0M held through his foundation are pledged to secure lines of credit, and 26.2M of Mitchell’s and 5.9M of the foundation shares as well. That is 66.1M shares in all, worth $15.5B, or 88% of the brothers’ holdings C (calculated). ¹⁴ The proxy says each is in compliance with the terms of those loans. I read that as meaning they have borrowed against much of their stake. It does not mean anything is wrong. It means a sharp, long fall in the price would matter to them in a way it would not to an unlevered holder.

The outgoing chief executive held 569,014 shares in the beneficial ownership table, and 481,507 of those were options. About 70,000 were shares he owned outright. On 7 August he adopted a trading plan covering up to 60,015 shares through 6 February 2027. ¹⁴³ The proxy sets stock ownership guidelines for executives. ¹⁴

What they did with capital over a full cycle

Ten years of reported cash flow tell the story. Operating cash flow added up to $56.9B. Acquisitions took $46.5B of it, or 82%. Dividends took $6.4B, and capital spending $9.7B. Buybacks were small until 2024, when the company bought $6.0B of stock, and $3.1B in 2025 C (calculated). ¹³⁸ The company also separated three businesses and gave the shares to holders: Fortive in 2016, Envista in 2019 and Veralto in 2023. ⁹⁸ Holders kept the value of those shares, and the figures on this page do not include it. The cash flow numbers are as first reported, and they include the separated businesses until each left.

What did the purchases cost, per dollar of sales they brought? I can only calculate it from what the company published. Cytiva was $20.7B, and it added 18.0 points to 2019’s $17.9B of sales in the nine months it was owned in 2020, about $3.2B, or $4.3B a year at that rate, so about 4.8 times sales C (calculated). ¹² Aldevron was $9.6B for about $300M of 2020 revenue, 32 times sales C (calculated). ¹¹ Abcam was $5.6B for about £362M of 2022 revenue, about 12 times if I take $1.25 to the pound, my assumption E (estimate). ⁹ Masimo was $9.8B for about $1.5B, 6.5 times C (calculated), and StatLab $1.4B for $250M, 5.6 times C (calculated). ³ These are high prices for sales, and the company’s own figures give a first sign of the result: Life Sciences, which holds IDT, Aldevron and Abcam, earned $520M in 2025 on $7.3B of sales, down from $1,209M in 2023. ⁸

I do not count this as a verdict. Buying a business at 30 times sales can pay if it grows for twenty years inside a better system. I count it as a reason to deduct something every year for the purchases, which is why my owner cash is after amortization. The record shows a management that has bought well in some places, such as Pall and Cytiva, which built the bioprocessing franchise, and paid up in others.

VFinancials

The first thing to see is that Danaher’s reported history changes shape. It separated Fortive in 2016, Envista in 2019 and Veralto in 2023, so the revenue line in each year’s 10-K covers a different company. I show each year as first reported, mark the breaks, and show the later restatements where I found them. A fall in revenue in 2019 or 2023 is a separation, not a decline.

Look at the shape. Revenue went from $16.9B in 2016 to $31.5B in 2022 as first reported, a rise helped by Cytiva, Aldevron and the COVID years. It then fell to $23.9B because Veralto left, and it has barely moved since: $23.9B, $23.9B, $24.6B. Operating margin before amortization peaked at 32.3% in 2022 and was 26.0% in 2025, or 28.3% before impairments C (calculated). ¹³⁸ The peak was helped by COVID testing, which I treat as a one-off.

Since the Veralto separation, revenue has grown from $23.9B in 2023 to $25.6B in the twelve months to September 2026, about 2.5% a year including the Abcam and Masimo purchases C (calculated). ⁸³ Net earnings from continuing operations fell from $4.2B in 2023 to $3.6B in 2025, which impairments, a rise in amortization and lower interest income explain in part, and adjusted EPS rose from $7.48 in 2024 to $7.80 in 2025 and is guided to $8.57 to $8.62 in 2026. ⁸⁷²

What an owner really takes out

Three numbers are used for Danaher’s profit. Adjusted earnings per share, the number most people quote, is guided to $8.57 to $8.62 in 2026, or about $6.1B. GAAP earnings from continuing operations were $3.1B in nine months and I estimate $4.2B for the year E (estimate), helped by $242M of one-off tax benefits. ² The third number is what I use. It is operating cash flow less capital spending, less stock pay, less amortization after tax. For 2026 that is about $4.0B, or $5.62 a share E (estimate). The yield on the market value of $166.0B is 2.4%.

The last line is almost exactly GAAP earnings. That is no accident: GAAP earnings are adjusted earnings less amortization, impairments and the rest. What the exercise shows is that cash flow looks stronger than GAAP earnings only because amortization is not a cash cost. If the amortization stands in for the money Danaher must spend on buying new technology to keep growing, then cash is no stronger than the income statement says. If it is only an accounting echo of past price, then the stronger figure is the real one. I do not know which is true, and I show both. My base is on the cautious basis. On the other, my base is $203 a share, not $157.

The capital needed to stand still

Capital spending was $1,156M in 2025, 1.5 times depreciation of $750M. In nine months of 2026 it was $761M against $597M C (calculated). ⁸³ I cannot separate how much of that spending keeps the plants running and how much builds capacity for growth. The company does not say. So I use depreciation, 3.1% of sales, as the stand-still figure, and charge the rest to growth, with capital spending falling from 3.8% of sales as growth slows. Working capital is another cost: receivables, inventory and payables net to about 21% of sales, so each added dollar of sales ties up about 21 cents C (calculated). ³

The balance sheet

Debt was $26.5B at 25 September 2026 against cash of $5.7B, so net debt was $20.8B, and $22.2B after StatLab C (calculated). At the end of 2025 it was $13.8B. ³⁸ To pay for Masimo the company issued €3.0B of notes in April at 3.250% to 4.000% for the fixed series, about CHF 2.4B of notes in June at 1.65% to 2.51%, took out a $5.0B 364-day credit line in April, and used commercial paper. ^1920183 Net interest was $104M in the third quarter and is guided to about $120M in the fourth C (calculated). ³² Net debt is about 2.6 times my estimate of 2026 profit before interest, tax, depreciation and amortization of $8.4B C (calculated). The 364-day line carries a leverage covenant of 0.65 to 1.00. ¹⁸ Nothing here looks stretched. The company says it is in compliance with its covenants. ³

Goodwill and acquired intangibles are $68.4B, 73% of total assets. If a business like Life Sciences or the Aldevron plant does not earn what was paid, the answer comes as an impairment charge. There were $562M of them in 2025. ³⁸

The share price

The Q4 2026 close was $234.93. The highest close in ten years was about $294 on 3 September 2021, and the 52-week range is $161.91 on 15 May to $242.05 on 21 January C (calculated). ¹²⁵ The low was 45% below the 2021 high. The stock has since risen 45% from that low, and sits 20% below the old high. Over ten years the price rose 3.5 times, about 13% a year before dividends, on a series adjusted for the Veralto distribution only. ¹

VIValuation

What would ruin it

Before any numbers I ask how this goes badly wrong for an owner. I see three ways, and I list them in the order I fear them.

One: the growth Danaher buys stops paying for itself. Two: the cycle and policy turn on bioprocessing, China and lab budgets together. Three: the price has already moved up a long way and asks for a lot.

First, the buying. Danaher put 82% of ten years of operating cash into acquisitions C (calculated). Its recent prices were 6.5 times sales for Masimo, 5.6 times for StatLab, and about 12 and 32 times for Abcam and Aldevron C (calculated). ¹¹⁹³ Say it keeps spending about $4.65B a year, the ten-year average, and what it buys earns 5% a year on cost instead of the 8.0% I need. Each dollar is then worth 63 cents. That wastes about $1.7B a year of value, or about $2.50 a share a year C (calculated). It is the hardest risk to price, because a bad purchase looks fine for years in the pay measures. Life Sciences, which holds Aldevron, Abcam and IDT, earned $520M in 2025 against $1,209M in 2023. ⁸ Gross debt is $8.1B higher than at the end of 2025. ³⁸

Second, the cycle. Biotechnology sales fell 6.0% in 2024 and rose 8.0% in 2025. ⁸ A 10% fall in Biotechnology sales at its 25.6% margin costs about $187M of profit, 2.5% of my 2026 adjusted operating profit C (calculated). That is survivable. The damage would come from what it signals: that the orders the company called mid-teens in the second quarter do not become sales, or that China, 10.7% of sales and down 16% in two years, goes the way of diagnostics. ⁵⁸ My bear case captures this as growth of 3.5% a year and a margin sliding to 27.5%. It is worth $91 a share.

Third, the price. The shares closed at $161.91 on 15 May and at $234.93 at the Q4 2026 close, a rise of 45% in under six months C (calculated). ¹ Over that time the company raised guidance twice, bought Masimo and named a new CEO. The first rise may be earned: orders are growing and the margin is up. Still, at 27 times adjusted earnings and 42 times what I think an owner keeps after amortization, the price already allows for several things going right. I can’t say why the market decided in May that it was wrong and now thinks it is right. A fall of 33% to my base, or 61% to my bear, has happened to this stock before: it fell 45% between September 2021 and May 2026. ¹

What the price implies

Market value at $234.93 is $166.0B on 706.4M diluted shares C (calculated). Add net debt of $22.2B and the business is priced at $188.2B. ¹³ To earn my 8.0%, owner cash after amortization, about $4.0B in 2026, needs to grow 10.5% a year for fifteen years and then 3% for ever E (estimate). Over the last nine years that same measure grew 7.3% a year, from $1.9B to $3.6B, and revenue grew 4.3% a year, in both cases as first reported and including $46.5B of purchases C (calculated). ¹³ So the price asks for 10.5% against a record of 7.3%, and the record includes the purchases. The $4.0B starting point is a 2026 figure that carries about $0.9B of working-capital and accrual outflows in nine months and only part of a year of Masimo, and my model’s 2027 figure is $4.5B, so the 10.5% depends on where you start. ³

The price asks for far more than my base: nearly three more points of growth every year, or ten more points of margin, for fifteen years.

The discount rate

I use 8.0%. The capital asset pricing model gives 8.2%: the 10-year Treasury at 4.90%, plus a beta of 0.75 from 119 months of returns against SPY, times Damodaran’s 4.41% implied premium for 1 November C (calculated). ²²²⁴²³ I round to the nearest half point, as I do on other pages. The 60-month beta of 0.76 gives 8.3%. Danaher’s debt is about 14% of its value, and a blend with after-tax debt would be nearer 7.6%. I could argue for 8.5%, since the company has a new CEO, took on $8B of extra debt this year, and sells 11% of its goods in China. I stay at 8.0% to give the price its best case, and I know that is a choice. At 7.5% my base is $179. At 8.5% it is $139. My Lilly, Novo Nordisk and Mastercard pages use 9.0% for large, established companies; at 9.0% this base is $124 and the price is 89% above it.

The price sits outside the table. It takes a discount rate of 6.6% to reach it with my base C (calculated). A reader who accepts 7.0% a year, 2.1 points over the Treasury, with 3.5% growth for ever, gets $227, still below the price. One who wants 8.5% will find the price 69% above $139.

What I cannot judge

Five things, and I would rather say so than give a false figure.

• How much of the capital spending is for upkeep and how much for growth. The company does not split it. Capital spending ran at 1.5 times depreciation in 2025. ⁸ My base assumes it falls from 3.8% of sales toward the stand-still level. I can’t test it.
• What the bought businesses earn after year one. The filings give goodwill, write-downs and the first-year effect on margin, not profit by deal. I can see that Life Sciences earned less in 2025 than in 2023, and not why in detail. ⁸³ My model gives the purchases no value beyond their cost.
• Whether bioprocessing orders become sales. The company says orders grew in the mid-teens in the second quarter, and sales grew less than that. It publishes no order number or backlog for the segment. ⁵⁴ If it all arrives, the base is low.
• China’s policy path. Diagnostics sales there fell with volume-based buying, and the company says the worst has passed. I cannot see the next round of rules. ⁸
• What the new CEO will do with the $26B of debt, the founders’ options and the balance sheet. She has given no plan on capital use except to aim for share gains. ² A change of direction away from buying would raise the cash I count and lower the growth.

Three cases

I value fifteen years of cash, 2027 to 2041, at 1 January 2027, then a growing perpetuity. Each year starts from revenue and takes the margin before amortization, after stock pay. From that I take $75M of expense on the special awards, acquisition amortization of $2.0B in 2027 growing 3% a year, and 18% tax. Then I add depreciation at 3.1% of sales and take off capital spending and working capital. I treat acquisitions as fairly priced, so they add no value beyond the amortization charge I deduct for them. Net debt of $20.3B comes off at the end.

Are these fair? Base revenue is $26.3B in 2026 and $28.4B in 2027, up 8.0% E (estimate). About 3.5 points of that is the full-year effect of Masimo and StatLab, which I can see, and 4.5 is core growth, which is more than the 2.5% of 2026 and in line with the company’s aim, stated in July, to exit 2026 at a mid-single-digit rate. ⁵² After 2027 the base runs at 5.5% to 6.0% for four years, then slows. Since the Veralto separation revenue has grown about 2.5% a year, so the base needs the growth to double, with some of it bought and paid for in the amortization I deduct. The base margin of 29.5% in 2027, rising to 31.5%, is a gain of 2.5 points over the 28.95% I estimate for 2026, which includes part of a year of Masimo at a lower margin. The 2022 peak was 32.3%, helped by COVID testing. So the base asks for growth to recover, for the margin to drift up, and for purchases to earn their cost.

What closes the gap

Two things get there, and neither is small. Bull growth alone gives $188 and a bull margin alone gives $174, both under the price. Together they give $213, and the price is still 10% higher. It takes the bull case and a decision not to count amortization as a cost, which gives $259, to cover it. The discount rate has to fall to 6.6% for my base to reach it. The price is a bet on near-perfect execution of the growth plan and on a lower required return.

How the odds shrink

The bull case needs several things to go right at once. These are my judgments.

That comes to about 2% E (estimate). The four are linked, since strong bioprocessing helps both growth and margin, so the true figure is higher. If I raise each to 75%, it is still 32% C (calculated). And the bull case, at $213, is still under the price. The price needs more than the bull: a lower required return, or no cost for amortization, as well.

The next best use of the dollar

The closest business on this site is Intuitive Surgical, which sells the same kind of recurring consumable to hospitals. Intuitive is the more concentrated business, one robot, and the page values it well below its price: 96% above my base at the 30 October close. Danaher’s gap is 50%, and its base cash flows return 6.6% against 8.0%, a shortfall of 1.4 points. McKesson’s base returns 7.6% against 8.0%, a shortfall of 0.4 points, at the price on its own page, with a toll-road business that needs no purchases. The Treasury pays 4.90% with none of the risk, so Danaher’s base pays about 1.7 points a year for taking it. The table is not a ranking, since the required rates differ, and I draw no more from it than that the base cash flows here fall further short than McKesson’s.

Quality and price

These are two questions. On quality, the record shows a broad set of businesses with recurring revenue of 83%, a margin before amortization near 29%, free cash flow of 92% to 95% of adjusted earnings, and a debt load it can carry. Against that, the return on all the capital in it is only 6.5% to 8.6% and core growth was 2.0% in 2025. On price, this looks like a good business at a price that already pays for the good news: 50% above my base, 10% above my bull, and 158% above my bear. Paying $234.93 earns about 6.6% in my base case, against the 8.0% I ask. A reader who values the stock on adjusted earnings of $8.60, a multiple of 27, will not find that unusual for a high-quality tools company, and I want to say so plainly. The difference is what you count as cost.

The margin of safety

I take 25% off base, which gives $117 E (estimate). I use 25% because the cash comes from many recurring lines. I do not use less because two of the large inputs cannot be known: the return on purchases and the new CEO’s plan. $117 is 29% above my bear of $91 C (calculated), so the bear gives little cushion. The stock last closed at or below that level on 1 April 2020, at $113.62 on the adjusted series C (calculated). ¹ I don’t expect it to go back there. If the market is right, it is because bioprocessing sales catch up with orders and the margin passes 31%, or because amortization proves to be an accounting echo and not a real cost, in which case my base of $203 without it is the better guide.

VIIThe case for the price

What most people miss

Three things cut in the company’s favour. First, the headline growth hides a swing that will not repeat. Respiratory tests were about $1.9B in 2025 and are guided to $1.5B in 2026, a headwind of low single digits, and without them core growth was 5.5% in the third quarter and is guided to a mid-single-digit rate for the year C (calculated). ² Second, the share count is falling. Diluted shares were 743M in 2023 and 706.8M in the third quarter of 2026, 4.9% fewer, from $9.1B of buybacks in 2024 and 2025 and $0.9B this year C (calculated). ¹³²³ Third, cash conversion is high: free cash flow was 95% of adjusted net earnings in 2025 and 92% in nine months of 2026 C (calculated). ⁷²

The bull case

The company’s own case is that the recovery is real and Danaher is early in it. In the third-quarter release the new CEO said the company delivered better-than-expected revenue, earnings and cash flow, that she is encouraged by improving trends across end markets, and that the aim is to become the defining leader in life sciences and diagnostics and to gain share. ² In July her predecessor said bioprocessing orders grew in the mid-teens in the second quarter and that he expected the company to exit 2026 at a mid-single-digit core growth rate. ⁵ The board backed the plan with a special program of options struck at the August price, which vest in four and five years. ¹⁵

Outside views I can use are thin. I did not find a dated, published case on this company from a named investor or analyst that I could check against a filing, and so I cite none. What I can check are holdings. At 30 June 2026 Third Point held 540,000 shares, worth $102.9M, a small rise on 525,000 at 31 March, and Tiger Global held a new 456,000 shares, worth $86.9M. ²⁶²⁷ Together that is about 0.14% of the company, and the filings say nothing about why. Of 18 well-known funds whose 13F filings I read, only these two and Duquesne Family Office, with a new 50,300 shares, held it at 30 June. ²⁸

Against reality

Much of that case is already in the price. Guided adjusted earnings of $8.57 to $8.62 are 10% above 2025’s $7.80, with core growth of only 2.5% C (calculated). ²⁷ My base has revenue growing 8.0% in 2027, with 4.5 points of it core, and 5.5% to 6.0% a year to 2031 E (estimate). If Danaher does that, holds the margin at 29.5% rising to 31.5%, and the purchases earn their cost, my $157 is possible. For $234.93 the company has to do more: the bull path, which gets $213, and the price is still 10% higher. The bull path covers it only if the required return falls to about 7.5%, or amortization is not counted as a cost.

The weak points of the case are three. Core growth was 2.0% in 2025 and the company’s best quarter in 2026 is 3.0%, 5.5% only without respiratory tests. ² Life Sciences core sales fell 1.5% in 2025. ⁸ And bioprocessing has so far shown mid-single-digit sales growth against mid-teens orders. ⁴³

What a 10x would take. Ten times the price is $2,349, a market value of $1.66T C (calculated). At 25 times owner cash after amortization, that needs $66B a year, 17 times the $4.0B of 2026, and at today’s ratio of owner cash to sales, about $439B of revenue against $26.3B C (calculated). In ten years that is 33% a year, about eight times the 4.3% a year Danaher grew in the last nine as first reported C (calculated). ¹³ For companies this size the record is thin. NVIDIA went from about $145B at the end of 2019 to a price 34 times higher in under seven years, on a new category of demand. ³¹³² Danaher’s own ten years took the price from $67.92 to $234.93, 3.5 times. ¹ I know of no life-science tools company that has grown by that factor from a base this large, and I did not find one in the filings I read. For Danaher, a tenfold rise is not plausible on anything I can see.

Where I come down

The 5.5% growth without respiratory tests and the mid-teens orders moved me. The jump in the share price since May did not, because I cannot tell what it says beyond optimism. The record of paying 6 to 32 times sales for businesses, and a Life Sciences segment that earns half what it did in 2023, kept my base where it is. What would raise my values is two quarters of core growth above 5% with the Life Sciences margin above 16%, and no new large deal. That would lift my base, though not to the price.

VIIIRisks, and what would change my view

In the order I weigh them.

1. The buying. $11.3B spent in 2026 on Masimo and StatLab, 6.5 and 5.6 times sales, on top of $46.5B in the ten years before. Another large deal could cost more than it brings. ³⁸
2. China. 11% of 2025 sales, down from 13% in 2023, with volume-based buying cutting prices in diagnostics and tariffs and export rules going both ways. ⁸
3. Bioprocessing timing. Large customers moved shipments between quarters in 2026. If orders do not follow through, the 2027 base is too high. ⁴⁵
4. Policy and funding. Academic and government demand is described as muted. Tariffs and court rulings on them changed during the year, and the company is now returning tariff refunds to customers. ³²
5. Diagnostics and respiratory tests. Core sales of Diagnostics rose 1.5% in 2025 and are guided to about flat in 2026. Respiratory sales ranged from $1.9B in 2025 to $1.5B in 2026. ⁸²
6. Leadership and pay. A new CEO, a new CFO, a board that grew to 13 and a special award for 2026 that the company leaves out of adjusted earnings. The founders own 10.7% and have pledged 88% of what they own against loans. ¹⁵¹⁶¹⁴
7. Debt. $26.5B of gross debt, with €3.0B and CHF 2.4B of new notes and a $5.0B 364-day facility. Net interest runs near $480M a year at the Q4 rate, against about $257M a year in nine months of 2025, annualized C (calculated). ^32181920
8. Taxes. The 10-K says a taxable finding on any of the Fortive, Envista or Veralto separations could be costly, that the IRS is examining 2016 to 2022, and that Danish authorities have assessed about $326M for 2004 to 2015. ⁸
9. Litigation. The securities class action over statements on bioprocessing revenue has settled, with approval in September 2026 and costs covered by insurance. ³
10. Valuation. The shares rose 45% in under six months, and they can give it back. ¹

If core growth passes 5% for two quarters and the Life Sciences margin heads back to 16%, I would move the base up, by perhaps a tenth. If the next two quarters show bioprocessing sales still lagging orders, or another large deal or write-down, I would move toward the bear. And if the price came to the mid-$100s, with the business unchanged, this page would read very differently.